ClinicalTrials.gg
CompletedNCT01352507Updated Apr 26, 2013Results posted

A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China

A Phase 4 interventional study of Tadalafil and Sildenafil in Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 9 sites in China. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-04-26.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
383
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing tadalafil in Erectile Dysfunction — 9 open to participants now, 9 under way, 3 of them phase 3. Tadalafil · Erectile Dysfunction.

Enrollment
15th of 56
383 · median 199
Started
2011
with 1 other
Phase 4
26 of 57
3 open now
Registered
30th of 57
by date
Lead sponsor
26 of 57
Eli Lilly and Company

Among the 57 studies testing tadalafil in Erectile Dysfunction, this one is the 15th largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2011, is one of 26 in phase 4, and was the 30th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

9 of the 57 studies testing tadalafil in Erectile Dysfunction are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing tadalafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate whether, after two 8-week treatment periods, male patients with erectile dysfunction (ED) in China prefer 20 milligram (mg) tadalafil or 100 mg sildenafil. This trial consists of two treatment periods of 8 weeks each and an extension phase of 8 weeks, for a total of 24 weeks.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study Subjects

  • Are able to read, understand and provide signed .
  • Have a history ED of any etiological classification (psychogenic, organic, or mixed) and any severity for at least 3 months.
  • Have never taken any phosphodiesterase 5 (PDE5) inhibitor for the treatment of ED.
  • Anticipate having the same female sexual partner during the study for recording responses to efficacy questionnaires. If a qualifying participant has more than one female partner during the study, the participant will not be excluded from the trial. However, the participant will be required to respond to the questionnaires based on his sexual interactions with only one of these partners.
  • Make at least 4 sexual intercourse attempts, with the female sexual study partner, during the 4-week run-in period and during the final 4 weeks of each 8-week treatment period.
  • Not use any ED treatment including the use of herbal therapy and traditional Chinese medicine (TCM) for the treatment of ED other than study medication at any time during the study and for 96 hours after study completion.

Partners

  • Are female, at least 18 years of age at screening and will have the same male study subject as her sexual partner during the study.
  • Are able to read, understand and provide signed informed consent.
  • Agree to make at least 4 sexual intercourse attempts with the male sexual study partner during the 4-week run-in phase and during the final 4 weeks of each 8-week treatment period.
  • Willing to participate in recording responses to efficacy questionnaires, sexual quality of life questionnaires and other instruments used in this study.

Exclusion criteria

Exclusion Criteria:

  • Present with ED caused by other primary sexual disorders including premature ejaculation or ED caused by untreated endocrine disease.
  • Have a history of radical prostatectomy, or other pelvic surgery with subsequent failure to achieve erection.
  • Have a history of penile implant.
  • Have a penile deformity in the opinion of the investigator.
  • Exhibit evidence of clinically significant renal insufficiency as determined by the investigator, or defined as receiving renal dialysis or having an estimated of less than (\<)30 milliliters per minute (mL/minute) at screening, as calculated by the local laboratory using the Cockcroft-Gault formula.
  • Exhibit evidence of active symptomatic hepatobiliary disease at Visit 1.
  • Exhibit greater than (>) 11 percent (%) at screening, in patients with a history of diabetes mellitus of any type.
  • Present with chronic stable angina treated with long-acting nitrates, or with chronic stable angina requiring short-acting nitrates in the last 90 days, or with angina occurring during sexual intercourse in the last 6 months.
  • Have met the criteria for unstable angina within 6 months before screening, or have a history of myocardial infarction or coronary artery bypass graft surgery within 90 days before screening, or percutaneous coronary intervention within 90 days before screening.
  • Have any supraventricular arrhythmia with an uncontrolled ventricular response (mean heart rate >100 bpm) at rest, or have any history of spontaneous or induced sustained ventricular tachycardia (heart rate >100 beats per minute (bpm) for greater than or equal [≥] to 30 seconds) despite medical or device therapy, or use an internal cardioverter-defibrillator.
  • Have a history of sudden cardiac arrest despite medical or device therapy.
  • Exhibit any evidence of congestive heart failure within 6 months before screening.
  • Have had a new or significant cardiac conduction defect within 90 days before screening.
  • Exhibit systolic blood pressure >170 or \<90 milliliters of mercury (mm Hg) or diastolic blood pressure >100 or \<50 mm Hg at screening, or have a history of malignant hypertension.
  • Have retinitis pigmentosa.
  • Have a history of significant central nervous system injuries (including stroke and spinal cord injury) within the last 6 months.
  • Have a history of (HIV) infection.
  • Have a condition that in the opinion of the investigator would interfere with the patient's ability to provide or comply with study instructions, would place the patient at increased risk, or might confound the interpretation of study results.
  • Currently receive treatment with nitrates, alpha [1]-adrenergic blockers (such as doxazosin), cancer chemotherapy, or antiandrogens (except finasteride taken as Propecia™ or Proscar® or Avodart® [dutasteride]).
  • Have a history of drug, alcohol, or substance abuse within the past 6 months, as assessed by the investigator.
  • Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
  • Patients who are currently taking TCM for ED treatment within the last 30 days prior to study entry or planned concomitant administration of TCM for ED treatment during study enrolment.
  • Are currently enrolled in, or discontinued with the last 30 days from a clinical trial involving an product or unapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. Patients who have been screen failures in other studies may be eligible if they satisfy the inclusion/exclusion criteria.
  • Have a history of loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure.
  • Have rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption lactose intolerance.
  • Are currently in a sexual relationship with a female of where no form of is being used. A female of child-bearing potential is a female who is not surgically or chemically sterilized and who is between menarche and 1-year post menopause.
  • Are currently in or are planning to be in a sexual relationship with a pregnant female or are currently in a relationship where either partner is actively trying to conceive.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
383 participants (actual)

Study arms

  • Experimental
    Tadalafil then Sildenafil

    20 mg tadalafil taken orally, as needed, for 8 weeks, followed by 100 mg sildenafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments. At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for erectile dysfunction (ED).

    Drug: Tadalafil · Drug: Sildenafil

  • Active comparator
    Sildenafil then Tadalafil

    100 mg sildenafil taken orally, as needed, for 8 weeks, followed by 20 mg tadalafil taken orally, as needed, for an additional 8 weeks. There is a washout period of 7-10 days between treatments. At the end of the two 8-week treatment periods, participants will be allowed to enter an 8-week extension phase on their preferred medication for ED.

    Drug: Tadalafil · Drug: Sildenafil

Interventions

  • Administered Orally

    Also known as: Cialis, LY450190

  • Administered Orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Preferring Tadalafil Over Sildenafil Measured at Week 18 Using Question 1 of the "Phosphodiesterase 5 Inhibitor Treatment Preference" Questionnaire (PITPQ)

    PITPQ Question (Q) 1 was a dichotomous outcome measure in which the participant selected his preferred study treatment (tadalafil or sildenafil) to receive during the Extension Phase.

    Time frame: Week 18

Secondary outcomes

  1. Percentage of Participants Moderately or Strongly Preferring the Selected Treatment at Week 18 Using Question 2 of the PITPQ

    PITPQ Q2 was a measure of the degree of treatment preference based on the participant's opinion. The question was, "For the treatment preference you selected in Q1, what is your degree of preference?". Choices were moderate or strong.

    Time frame: Week 18

  2. Change in International Index of Erectile Function (IIEF) Overall Satisfaction Domain

    Self-reported overall satisfaction over the past 4 weeks. IIEF overall satisfaction was the sum of Q13 and Q14. Scores ranged from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Change was defined as endpoint minus baseline domain score. Change in IIEF overall satisfaction domain at Week 8 and Week 18 were averaged to produce an overall change in IIEF overall satisfaction domain score. Higher IIEF overall satisfaction domain scores were indicative of greater overall satisfaction.

    Time frame: Baseline, Week 8, and Week 18

  3. Change in Sexual Encounter Profile (SEP) Question 2

    Participant-assessed diary that assessed the mean change from baseline in the percentage of "yes" responses to SEP Q2, "Were you able to insert your penis into your partner's vagina?". The SEP Q2 score was determined as the percentage of "yes" responses to SEP Q2 out of all sexual attempts recorded during the time period. Change was defined as the percentage of "yes" responses at endpoint minus the percentage of "yes" responses at baseline. Change in percentage of "yes" responses to SEP Q2 at Week 8 and Week 18 were averaged to produce an overall change in SEP Q2.

    Time frame: Baseline, Week 8, and Week 18

  4. Change in Psychosocial and Interpersonal Relationship Scale (PAIRS) Sexual Self-Confidence Domain

    PAIRS was a self-administered, 29-item scale that assessed the broader psychological and interpersonal outcomes associated with ED and its treatment. Each question was rated on a Likert scale that ranged from 1 (strongly disagree) to 4 (strongly agree). The sexual self-confidence domain score was the average score for Items 5, 10, 15, 23, 27, and 29. Sexual self-confidence domain scores ranged from 1 (strongly disagree) to 4 (strongly agree). Change was defined as endpoint minus baseline domain score. Change in PAIRS sexual self-confidence domain scores at Week 8 and Week 18 were averaged to produce an overall change in PAIRS sexual self-confidence domain score. Higher scores were indicative of greater sexual self-confidence.

    Time frame: Baseline, Week 8, and Week 18

  5. Drug Attributes Questionnaire (DRAQ) at Week 18

    DRAQ was a questionnaire used to record explanations for why participants preferred a drug. Participants identified their first and second reasons for drug preference from a choice of 7 reasons. Each reason for drug preference includes participants who selected that reason as their first or second reason.

    Time frame: Week 18

  6. Change in International Index of Erectile Function (IIEF) Intercourse Satisfaction Domain

    Self-reported intercourse satisfaction over the past 4 weeks. IIEF intercourse satisfaction was the sum of Q6, Q7, and Q8 of the IIEF. Scores ranged from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions ranging from 0 to 15. Change was defined as endpoint minus baseline domain score. Change in IIEF intercourse satisfaction domain at Week 8 and Week 18 were averaged to produce an overall change in IIEF intercourse satisfaction domain score. Higher scores were indicative of an increase in intercourse satisfaction.

    Time frame: Baseline, Week 8, and Week 18

  7. Change in International Index of Erectile Function (IIEF) Sexual Desire Domain

    Self-reported sexual desire over the past 4 weeks. IIEF sexual desire was the sum of Q11 and Q12. Scores ranged from 1 (low/almost never) to 5 (very high/almost always) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Change was defined as endpoint minus baseline domain score. Change in IIEF sexual desire domain at Week 8 and Week 18 were averaged to produce an overall change in IIEF sexual desire domain score. Higher scores were indicative of increased sexual desire.

    Time frame: Baseline, Week 8, and Week 18

  8. Change in International Index of Erectile Function (IIEF) Orgasmic Function Domain

    Self-reported orgasmic function over the past 4 weeks. IIEF orgasmic function was the sum of Q9 and Q10 of the IIEF. Scores ranged from 0 (no stimulation) to 5 (almost always) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Change was defined as endpoint minus baseline domain score. Change in IIEF orgasmic function domain at Week 8 and Week 18 were averaged to produce an overall change in IIEF orgasmic function domain score. Higher scores were indicative of better orgasmic function.

    Time frame: Baseline, Week 8, and Week 18

  9. Change in Sexual Encounter Profile (SEP) Question 3

    Participant-assessed diary that assessed the mean change from baseline in the percentage of "yes" responses to SEP Q3, "Did your erection last long enough for you to have successful intercourse?". The SEP Q3 score was determined as the percentage of "yes" responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of "yes" responses at endpoint minus percentage of "yes" responses at baseline. Change in the percentage of "yes" responses to SEP Q3 at Week 8 and Week 18 were averaged to produce an overall change in SEP Q3.

    Time frame: Baseline, Week 8, and Week 18

  10. Change in PAIRS Spontaneity Domain

    PAIRS was a self-administered, 29-item scale that assessed the broader psychological and interpersonal outcomes associated with ED and its treatment. Each question was rated on a Likert scale that ranged from 1 (strongly disagree) to 4 (strongly agree). The spontaneity domain score was the average score for Items 3, 12, 13, 16, 17, 19, 21, 22, and 28. Spontaneity domain scores ranged from 1 (strongly disagree) to 4 (strongly agree). Change was defined as endpoint minus baseline domain score. Change in PAIRS spontaneity domain at Week 8 and Week 18 were averaged to produce an overall change in PAIRS spontaneity domain score. Higher scores were indicative of greater spontaneity.

    Time frame: Baseline, Week 8, and Week 18

  11. Change in PAIRS Time Concerns Domain

    PAIRS was a self-administered, 29-item scale that assessed the broader psychological and interpersonal outcomes associated with ED and its treatment. Each question was rated on a Likert scale that ranged from 1 (strongly disagree) to 4 (strongly agree). The time concerns domain score was the average score for Items 1, 2, 6, 7, 8, 20, 24, and 25. Time concern domain scores ranged from 1 (strongly disagree) to 4 (strongly agree). Change was defined as endpoint minus baseline domain score. Change in PAIRS time concerns at Week 8 and Week 18 were averaged to produce an overall change in PAIRS time concerns domain score. Higher scores were indicative of more time concerns.

    Time frame: Baseline, Week 8, and Week 18

  12. Change in International Index of Erectile Function (IIEF) Erectile Function Domain

    Self-reported erectile function over the past 4 weeks. IIEF erectile function was the sum of Q1 through Q5 and Q15 of the IIEF. Q1 through Q5 were scored 0 (low/no erectile function) to 5 (high erectile function) and Q15 was scored 1 (no/low confidence) to 5 (high confidence). IIEF erectile function domain scores ranged from 1 to 30. Change was defined as endpoint minus baseline domain score. Change in IIEF erectile function domain at Week 8 and Week 18 were averaged to produce an overall change in IIEF EF domain score. Higher scores were indicative of better erectile function.

    Time frame: Baseline, Week 8, and Week 18

07

Results

Posted Apr 26, 2013

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneTadalafil Then SildenafilSildenafil Then Tadalafil
Started190193
Received treatment182188
Completed176184
Not completed149
Withdrew: Adverse event30
Withdrew: Lost to follow-up34
Withdrew: Withdrawal by subject75
Withdrew: Physician decision10
Washout Period
Participant flow — Washout Period
MilestoneTadalafil Then SildenafilSildenafil Then Tadalafil
Started176184
Completed176183
Not completed01
Withdrew: Withdrawal by subject01
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneTadalafil Then SildenafilSildenafil Then Tadalafil
Started176183
Received treatment173181
Completed170180
Not completed63
Withdrew: Entry criteria not met10
Withdrew: Withdrawal by subject43
Withdrew: Lack of efficacy10
Extension Phase
Participant flow — Extension Phase
MilestoneTadalafil Then SildenafilSildenafil Then Tadalafil
Started164173
Completed164173
Not completed00

Outcome measures

PrimaryPercentage of Participants Preferring Tadalafil Over Sildenafil Measured at Week 18 Using Question 1 of the "Phosphodiesterase 5 Inhibitor Treatment Preference" Questionnaire (PITPQ)

PITPQ Question (Q) 1 was a dichotomous outcome measure in which the participant selected his preferred study treatment (tadalafil or sildenafil) to receive during the Extension Phase.

Time frame:
Week 18
Reported as:
Number · percentage of participants
Percentage of Participants Preferring Tadalafil Over Sildenafil Measured at Week 18 Using Question 1 of the "Phosphodiesterase 5 Inhibitor Treatment Preference" Questionnaire (PITPQ)
percentage of participantsAll Randomized Participants
Percentage of Participants Preferring Tadalafil Over Sildenafil Measured at Week 18 Using Question 1 of the "Phosphodiesterase 5 Inhibitor Treatment Preference" Questionnaire (PITPQ)69.1 (64 to 74)
Statistical analysis
  • All Randomized Participants · Wilson Score method · p = <0.001
SecondaryPercentage of Participants Moderately or Strongly Preferring the Selected Treatment at Week 18 Using Question 2 of the PITPQ

PITPQ Q2 was a measure of the degree of treatment preference based on the participant's opinion. The question was, "For the treatment preference you selected in Q1, what is your degree of preference?". Choices were moderate or strong.

Time frame:
Week 18
Reported as:
Number · percentage of participants
Percentage of Participants Moderately or Strongly Preferring the Selected Treatment at Week 18 Using Question 2 of the PITPQ
percentage of participantsTadalafilSildenafil
Strong preference38.034.3
Moderate preference62.065.7
SecondaryChange in International Index of Erectile Function (IIEF) Overall Satisfaction Domain

Self-reported overall satisfaction over the past 4 weeks. IIEF overall satisfaction was the sum of Q13 and Q14. Scores ranged from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Change was defined as endpoint minus baseline domain score. Change in IIEF overall satisfaction domain at Week 8 and Week 18 were averaged to produce an overall change in IIEF overall satisfaction domain score. Higher IIEF overall satisfaction domain scores were indicative of greater overall satisfaction.

Time frame:
Baseline, Week 8, and Week 18
Reported as:
Mean · units on a scale
Change in International Index of Erectile Function (IIEF) Overall Satisfaction Domain
units on a scaleTadalafilSildenafil
Change in International Index of Erectile Function (IIEF) Overall Satisfaction Domain3.74 ± 1.943.71 ± 2.05
Statistical analysis
  • Tadalafil vs Sildenafil · Mixed Models Analysis · p = 0.793 (P-Value and LS mean difference were from a crossover mixed effect model that included treatment, period, sequence, and site as fixed effects, baseline value of efficacy measure as covariate, and participant within sequence as random effect.) · Least squares (ls) mean difference: 0.02 · 95% CI -0.11 to 0.15
SecondaryChange in Sexual Encounter Profile (SEP) Question 2

Participant-assessed diary that assessed the mean change from baseline in the percentage of "yes" responses to SEP Q2, "Were you able to insert your penis into your partner's vagina?". The SEP Q2 score was determined as the percentage of "yes" responses to SEP Q2 out of all sexual attempts recorded during the time period. Change was defined as the percentage of "yes" responses at endpoint minus the percentage of "yes" responses at baseline. Change in percentage of "yes" responses to SEP Q2 at Week 8 and Week 18 were averaged to produce an overall change in SEP Q2.

Time frame:
Baseline, Week 8, and Week 18
Reported as:
Mean · percentage of "yes" responses
Change in Sexual Encounter Profile (SEP) Question 2
percentage of "yes" responsesTadalafilSildenafil
Change in Sexual Encounter Profile (SEP) Question 245.28 ± 42.0344.94 ± 41.62
Statistical analysis
  • Tadalafil vs Sildenafil · Mixed Models Analysis · p = 0.988 (P-Value and LS mean difference were from a crossover mixed effect model that included treatment, period, sequence, and site as fixed effects, baseline value of efficacy measure as covariate, and participant within sequence as random effect.) · Ls mean difference: 0.01 · 95% CI -1.35 to 1.37
SecondaryChange in Psychosocial and Interpersonal Relationship Scale (PAIRS) Sexual Self-Confidence Domain

PAIRS was a self-administered, 29-item scale that assessed the broader psychological and interpersonal outcomes associated with ED and its treatment. Each question was rated on a Likert scale that ranged from 1 (strongly disagree) to 4 (strongly agree). The sexual self-confidence domain score was the average score for Items 5, 10, 15, 23, 27, and 29. Sexual self-confidence domain scores ranged from 1 (strongly disagree) to 4 (strongly agree). Change was defined as endpoint minus baseline domain score. Change in PAIRS sexual self-confidence domain scores at Week 8 and Week 18 were averaged to produce an overall change in PAIRS sexual self-confidence domain score. Higher scores were indicative of greater sexual self-confidence.

Time frame:
Baseline, Week 8, and Week 18
Reported as:
Mean · units on a scale
Change in Psychosocial and Interpersonal Relationship Scale (PAIRS) Sexual Self-Confidence Domain
units on a scaleTadalafilSildenafil
Change in Psychosocial and Interpersonal Relationship Scale (PAIRS) Sexual Self-Confidence Domain0.75 ± 0.650.72 ± 0.62
Statistical analysis
  • Tadalafil vs Sildenafil · Mixed Models Analysis · p = 0.102 (P-Value and LS mean difference were from a crossover mixed effect model that included treatment, period, sequence, and site as fixed effects, baseline value of efficacy measure as covariate, and participant within sequence as random effect.) · Ls mean difference: 0.03 · 95% CI -0.01 to 0.08
SecondaryDrug Attributes Questionnaire (DRAQ) at Week 18

DRAQ was a questionnaire used to record explanations for why participants preferred a drug. Participants identified their first and second reasons for drug preference from a choice of 7 reasons. Each reason for drug preference includes participants who selected that reason as their first or second reason.

Time frame:
Week 18
Reported as:
Number · percentage of participants
Drug Attributes Questionnaire (DRAQ) at Week 18
percentage of participantsTadalafilSildenafil
Time between drug and first erection was short10.335.2
Was able to get an erection long after having drug55.011.1
Had erections the next morning24.011.1
The firmness of erections36.451.9
Was able to get an erection every time37.656.5
Had few side effects23.625.9
Partner preferred this treatment10.77.4
SecondaryChange in International Index of Erectile Function (IIEF) Intercourse Satisfaction Domain

Self-reported intercourse satisfaction over the past 4 weeks. IIEF intercourse satisfaction was the sum of Q6, Q7, and Q8 of the IIEF. Scores ranged from 0 (low/no satisfaction) to 5 (high satisfaction) for each question, with the total possible score for the 3 questions ranging from 0 to 15. Change was defined as endpoint minus baseline domain score. Change in IIEF intercourse satisfaction domain at Week 8 and Week 18 were averaged to produce an overall change in IIEF intercourse satisfaction domain score. Higher scores were indicative of an increase in intercourse satisfaction.

Time frame:
Baseline, Week 8, and Week 18
Reported as:
Mean · units on a scale
Change in International Index of Erectile Function (IIEF) Intercourse Satisfaction Domain
units on a scaleTadalafilSildenafil
Change in International Index of Erectile Function (IIEF) Intercourse Satisfaction Domain5.88 ± 3.025.91 ± 3.03
Statistical analysis
  • Tadalafil vs Sildenafil · Mixed Models Analysis · p = 0.861 (P-Value and LS mean difference were from a crossover mixed effect model that included treatment, period, sequence, and site as fixed effects, baseline value of efficacy measure as covariate, and participant within sequence as random effect.) · Ls mean difference: -0.01 · 95% CI -0.22 to 0.19
SecondaryChange in International Index of Erectile Function (IIEF) Sexual Desire Domain

Self-reported sexual desire over the past 4 weeks. IIEF sexual desire was the sum of Q11 and Q12. Scores ranged from 1 (low/almost never) to 5 (very high/almost always) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Change was defined as endpoint minus baseline domain score. Change in IIEF sexual desire domain at Week 8 and Week 18 were averaged to produce an overall change in IIEF sexual desire domain score. Higher scores were indicative of increased sexual desire.

Time frame:
Baseline, Week 8, and Week 18
Reported as:
Mean · units on a scale
Change in International Index of Erectile Function (IIEF) Sexual Desire Domain
units on a scaleTadalafilSildenafil
Change in International Index of Erectile Function (IIEF) Sexual Desire Domain2.55 ± 2.112.60 ± 2.10
Statistical analysis
  • Tadalafil vs Sildenafil · Mixed Models Analysis · p = 0.495 (P-Value and LS mean difference were from a crossover mixed effect model that included treatment, period, sequence, and site as fixed effects, baseline value of efficacy measure as covariate, and participant within sequence as random effect.) · Ls mean difference: -0.05 · 95% CI -0.19 to 0.09
SecondaryChange in International Index of Erectile Function (IIEF) Orgasmic Function Domain

Self-reported orgasmic function over the past 4 weeks. IIEF orgasmic function was the sum of Q9 and Q10 of the IIEF. Scores ranged from 0 (no stimulation) to 5 (almost always) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Change was defined as endpoint minus baseline domain score. Change in IIEF orgasmic function domain at Week 8 and Week 18 were averaged to produce an overall change in IIEF orgasmic function domain score. Higher scores were indicative of better orgasmic function.

Time frame:
Baseline, Week 8, and Week 18
Reported as:
Mean · units on a scale
Change in International Index of Erectile Function (IIEF) Orgasmic Function Domain
units on a scaleTadalafilSildenafil
Change in International Index of Erectile Function (IIEF) Orgasmic Function Domain3.70 ± 2.823.71 ± 2.76
Statistical analysis
  • Tadalafil vs Sildenafil · Mixed Models Analysis · p = 0.917 (P-Value and LS mean difference were from a crossover mixed effect model that included treatment, period, sequence, and site as fixed effects, baseline value of efficacy measure as covariate, and participant within sequence as random effect.) · Ls mean difference: -0.01 · 95% CI -0.18 to 0.16
SecondaryChange in Sexual Encounter Profile (SEP) Question 3

Participant-assessed diary that assessed the mean change from baseline in the percentage of "yes" responses to SEP Q3, "Did your erection last long enough for you to have successful intercourse?". The SEP Q3 score was determined as the percentage of "yes" responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of "yes" responses at endpoint minus percentage of "yes" responses at baseline. Change in the percentage of "yes" responses to SEP Q3 at Week 8 and Week 18 were averaged to produce an overall change in SEP Q3.

Time frame:
Baseline, Week 8, and Week 18
Reported as:
Mean · percentage of "yes" responses
Change in Sexual Encounter Profile (SEP) Question 3
percentage of "yes" responsesTadalafilSildenafil
Change in Sexual Encounter Profile (SEP) Question 364.53 ± 38.3763.72 ± 37.66
Statistical analysis
  • Tadalafil vs Sildenafil · Mixed Models Analysis · p = 0.391 (P-Value and LS mean difference were from a crossover mixed effect model that included treatment, period, sequence, and site as fixed effects, baseline value of efficacy measure as covariate, and participant within sequence as random effect.) · Ls mean difference: 1.23 · 95% CI -1.58 to 4.04
SecondaryChange in PAIRS Spontaneity Domain

PAIRS was a self-administered, 29-item scale that assessed the broader psychological and interpersonal outcomes associated with ED and its treatment. Each question was rated on a Likert scale that ranged from 1 (strongly disagree) to 4 (strongly agree). The spontaneity domain score was the average score for Items 3, 12, 13, 16, 17, 19, 21, 22, and 28. Spontaneity domain scores ranged from 1 (strongly disagree) to 4 (strongly agree). Change was defined as endpoint minus baseline domain score. Change in PAIRS spontaneity domain at Week 8 and Week 18 were averaged to produce an overall change in PAIRS spontaneity domain score. Higher scores were indicative of greater spontaneity.

Time frame:
Baseline, Week 8, and Week 18
Reported as:
Mean · units on a scale
Change in PAIRS Spontaneity Domain
units on a scaleTadalafilSildenafil
Change in PAIRS Spontaneity Domain0.33 ± 0.530.20 ± 0.42
Statistical analysis
  • Tadalafil vs Sildenafil · Mixed Models Analysis · p = <0.001 (P-Value and LS mean difference were from a crossover mixed effect model that included treatment, period, sequence, and site as fixed effects, baseline value of efficacy measure as covariate, and participant within sequence as random effect.) · Ls mean difference: 0.13 · 95% CI 0.09 to 0.18
SecondaryChange in PAIRS Time Concerns Domain

PAIRS was a self-administered, 29-item scale that assessed the broader psychological and interpersonal outcomes associated with ED and its treatment. Each question was rated on a Likert scale that ranged from 1 (strongly disagree) to 4 (strongly agree). The time concerns domain score was the average score for Items 1, 2, 6, 7, 8, 20, 24, and 25. Time concern domain scores ranged from 1 (strongly disagree) to 4 (strongly agree). Change was defined as endpoint minus baseline domain score. Change in PAIRS time concerns at Week 8 and Week 18 were averaged to produce an overall change in PAIRS time concerns domain score. Higher scores were indicative of more time concerns.

Time frame:
Baseline, Week 8, and Week 18
Reported as:
Mean · units on a scale
Change in PAIRS Time Concerns Domain
units on a scaleTadalafilSildenafil
Change in PAIRS Time Concerns Domain-0.28 ± 0.54-0.14 ± 0.49
Statistical analysis
  • Tadalafil vs Sildenafil · Mixed Models Analysis · p = <0.001 (P-Value and LS mean difference were from a crossover mixed effect model that included treatment, period, sequence, and site as fixed effects, baseline value of efficacy measure as covariate, and participant within sequence as random effect.) · Ls mean difference: -0.14 · 95% CI -0.19 to -0.09
SecondaryChange in International Index of Erectile Function (IIEF) Erectile Function Domain

Self-reported erectile function over the past 4 weeks. IIEF erectile function was the sum of Q1 through Q5 and Q15 of the IIEF. Q1 through Q5 were scored 0 (low/no erectile function) to 5 (high erectile function) and Q15 was scored 1 (no/low confidence) to 5 (high confidence). IIEF erectile function domain scores ranged from 1 to 30. Change was defined as endpoint minus baseline domain score. Change in IIEF erectile function domain at Week 8 and Week 18 were averaged to produce an overall change in IIEF EF domain score. Higher scores were indicative of better erectile function.

Time frame:
Baseline, Week 8, and Week 18
Reported as:
Mean · units on a scale
Change in International Index of Erectile Function (IIEF) Erectile Function Domain
units on a scaleTadalafilSildenafil
Change in International Index of Erectile Function (IIEF) Erectile Function Domain12.03 ± 6.7511.86 ± 6.68
Statistical analysis
  • Tadalafil vs Sildenafil · Mixed Models Analysis · p = 0.364 (P-Value and LS mean difference were from a crossover mixed effect model that included treatment, period, sequence, and site as fixed effects, baseline value of efficacy measure as covariate, and participant within sequence as random effect.) · Ls mean difference: 0.18 · 95% CI -0.20 to 0.55

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tadalafil (Treatment Periods)—0/363 (0%)30/363 (8.3%)
Sildenafil (Treatment Periods)—0/361 (0%)26/361 (7.2%)
Tadalafil (Extension Phase)—0/231 (0%)7/231 (3%)
Sildenafil (Extension Phase)—0/106 (0%)2/106 (1.9%)
Most frequent other events
Showing 10 of 35
Most frequent other events
EventTadalafil (Treatment Periods)Sildenafil (Treatment Periods)Tadalafil (Extension Phase)Sildenafil (Extension Phase)
HeadacheNervous system disorders10/3635/3612/2310/106
FlushingVascular disorders2/3636/3610/2311/106
DizzinessNervous system disorders6/3633/3612/2310/106
Face oedemaGeneral disorders1/3631/3610/2311/106
Nasal congestionRespiratory, thoracic and mediastinal disorders3/3633/3611/2310/106
Eye swellingEye disorders3/3630/3611/2310/106
Ocular hyperaemiaEye disorders0/3632/3610/2310/106
DyspepsiaGastrointestinal disorders1/3632/3610/2310/106
NauseaGastrointestinal disorders1/3632/3611/2310/106
PyrexiaGeneral disorders0/3632/3610/2310/106

Baseline characteristics

All randomized participants.

Age Continuous
Age Continuous(years)Tadalafil Then SildenafilSildenafil Then TadalafilTotal
Mean39.20 ± 10.5240.66 ± 11.4439.94 ± 11.00
Sex: Female, Male
Sex: Female, Male(Participants)Tadalafil Then SildenafilSildenafil Then TadalafilTotal
Female000
Male190193383
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Tadalafil Then SildenafilSildenafil Then TadalafilTotal
Chinese190193383
Region of Enrollment
Region of Enrollment(participants)Tadalafil Then SildenafilSildenafil Then TadalafilTotal
China190193383
International Index of Erectile Function (IIEF) Erectile Function (EF) Domain
International Index of Erectile Function (IIEF) Erectile Function (EF) Domain(units on a scale)Tadalafil Then SildenafilSildenafil Then TadalafilTotal
Mean13.77 ± 5.3714.19 ± 6.0813.98 ± 5.73
Erectile Dysfunction (ED) Severity
Erectile Dysfunction (ED) Severity(participants)Tadalafil Then SildenafilSildenafil Then TadalafilTotal
Mild6368131
Moderate6865133
Severe5960119
ED Duration
ED Duration(participants)Tadalafil Then SildenafilSildenafil Then TadalafilTotal
≥3 months to <1 year7787164
≥1 year113106219
ED Etiology
ED Etiology(participants)Tadalafil Then SildenafilSildenafil Then TadalafilTotal
Psychogenic464187
Organic111324
Mixed133139272
08

Study locations

9 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100853, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410008, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hangzhou, 310003, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanjing, 210008, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200080, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shenzhen, 518036, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tianjin, 300211, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wu Han, 430030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Xi'An, 710004, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Jun 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2013, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2011
First posted
May 12, 2011
Start
Jun 2011
Primary completionActual
Jun 2012
CompletionActual
Jul 2012
Results first posted
Apr 26, 2013
Last update
Apr 26, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01352507
Responsible party
Sponsor
First posted
May 12, 2011
Start date
Jun 2011
Primary completion
Jun 2012
Completion
Jul 2012
Results posted
Apr 26, 2013
Last update
Apr 26, 2013

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tadalafil · Sildenafil

Start the discussion